V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010908 | 330005837 | 1.58 | 109 | null | 2016-03-11 | 2016-03-19 | VIDE | 02 | N | 330024124 | DOXORUBICIN + IFOSFAMIDE |
| 330010909 | 330005837 | 1.49 | 75.7 | Curative (C) | 2013-12-16 | 2014-04-09 | IMATINIB | N | null | 330024124 | UKALL2014 |
| 330010910 | 330009180 | 1.57 | 60 | Curative (C) | 2016-11-05 | 2016-11-10 | Capecitabine + Streptozocin | 2 | N | 330024126 | DACARBAZINE |
| 330010911 | 330009180 | 1.7 | 57 | Neo-adjuvant (N) | 2018-02-08 | 2018-02-26 | Hydroxycarbamide | 02 | N | 330024126 | UKALL2014 |
| 330010912 | 330005840 | 1.66 | 74 | null | 2015-10-27 | 2015-11-03 | Carboplatin + Thiotepa + Topotecan | 02 | N | 330024135 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE |
| 330010913 | 330005840 | 1.65 | 73.7 | Neo-adjuvant (N) | 2018-01-16 | 2018-02-14 | AML 19 TRIAL | 2 | N | 330024135 | CISPLATIN + GEMCITABINE |
| 330010916 | 330009184 | 0 | null | Curative (C) | 2017-07-13 | 2017-07-13 | VIDE | 02 | N | 330024179 | HYDROXYCARBAMIDE |
| 330010917 | 330005847 | null | 61.7 | Curative (C) | 2015-07-09 | 2015-07-21 | EMA/CO | N | N | 330024190 | EMA |
| 330010918 | 330005848 | 1.82 | 77 | Curative (C) | 2017-12-22 | 2018-02-26 | CYCLOPHOSPHAMIDE | N | N | 330024190 | CARBOPLATIN + CETUXIMAB + FU |
| 330010919 | 330012561 | 1.56 | 58.2 | Palliative (P) | 2014-08-11 | 2014-08-11 | VDC | 2 | N | 330024194 | PILOT TRIAL |
| 330010920 | 330005850 | 1.68 | 61.5 | Palliative (P) | 2018-03-03 | 2018-06-15 | Cytarabine Low Dose | 2 | N | 330024210 | CYTARABINE IT + METHOTREXATE |
| 330010921 | 330005852 | 1.69 | 60 | Palliative (P) | 2015-10-22 | 2015-10-22 | ALL UKALL2011 Maintenance B1 | 2 | N | 330024239 | BEP |
| 330010922 | 330009191 | 1.82 | null | Curative (C) | 2013-11-13 | 2013-11-13 | AML 18 TRIAL | 2 | N | 330024241 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330010923 | 330005855 | null | null | Curative (C) | 2017-04-28 | 2017-05-12 | Vinorelbine (oral) | N | N | 330024241 | RMS 2005 TRIAL |
| 330010924 | 330005857 | 0 | 98.1 | Curative (C) | 2013-06-17 | 2013-06-27 | PAC-PLAT | N | N | 330024264 | CYTARABINE |
| 330010925 | 330005860 | null | 28.4 | Curative (C) | 2017-11-30 | 2018-01-11 | BUSULFAN + MELPHALAN | N | N | 330024272 | DOXORUBICIN + HD MTX |
| 330010926 | 330005861 | 1.73 | 64 | Curative (C) | null | 2016-01-15 | Hydroxycarbamide | N | null | 330024278 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330010927 | 330005863 | 1.67 | 44.6 | Curative (C) | 2019-01-08 | 2019-02-16 | Cytarabine intrathecal | 02 | N | 330024281 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330010928 | 330005869 | 1.66 | null | Palliative (P) | 2014-12-12 | 2014-12-30 | LENALIDOMIDE + dexamethasone | N | N | 330024307 | EMA |
| 330010929 | 330009199 | 1.56 | 74.6 | Palliative (P) | 2013-10-14 | 2013-10-26 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330024316 | TOPOTECAN |
| 330010930 | 330005873 | 1.87 | 106 | Palliative (P) | 2014-12-09 | 2014-12-19 | Lenalidomide Cycle 26 onwards (PAS) | 02 | N | 330024319 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330010931 | 330005876 | 1.64 | null | Curative (C) | 2013-11-02 | 2013-12-14 | CYTARABINE | N | N | 330024370 | VINCRISTINE |
| 330010932 | 330005878 | 1.85 | 0 | null | 2016-03-08 | 2016-03-08 | Ifosfamide | N | null | 330024378 | FBC |
| 330010933 | 330005882 | null | 12.8 | Palliative (P) | 2016-08-01 | 2016-08-07 | Doxorubicin + Olaratumab | N | N | 330024385 | EMA/CO |
| 330010934 | 330005885 | 1.68 | 68.35 | Palliative (P) | 2016-03-16 | 2016-07-13 | Doxorubicin + Gemcitabine | Y | N | 330024390 | HYDROXYCARBAMIDE |
| 330010935 | 330005888 | 1.77 | 53.8 | Palliative (P) | 2015-06-14 | 2015-08-30 | Carboplatin + Thiotepa + Topotecan | N | null | 330024396 | CARBOPLATIN + CETUXIMAB + FU |
| 330010936 | 330005889 | 1.81 | 68.3 | null | 2015-06-08 | 2015-06-22 | BEP 5 Day | Y | N | 330024412 | IFOSFAMIDE |
| 330010937 | 330005892 | 1.78 | 85 | Curative (C) | 2016-08-14 | 2016-08-20 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 330024413 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330010938 | 330012887 | 1.81 | 86.4 | Disease modification (D) | null | 2018-02-01 | DABRAFENIB + TRAMETINIB | null | null | 330024433 | BORTEZOMIB |
| 330010939 | 330012887 | 1.67 | null | Curative (C) | 2013-08-06 | 2013-10-09 | Triple Intrathecal | N | N | 330024433 | CAPECITABINE + CARBOPLATIN + RT |
| 330010940 | 330011994 | 1.68 | 74 | Curative (C) | 2015-01-08 | 2015-01-14 | Cyclophosphamide High Dose | N | N | 330024452 | HYDROXYCARBAMIDE |
| 330010942 | 330005896 | 1.67 | 71 | Palliative (P) | 2014-08-09 | 2014-08-09 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | N | 330024475 | DOXORUBICIN + GEMCITABINE |
| 330010943 | 330011995 | 1.03 | 83 | Adjuvant (A) | null | 2017-09-13 | VIDE | null | null | 330024481 | AML17 TRIAL |
| 330010945 | 330005901 | null | 69.8 | Adjuvant (A) | 2015-12-11 | 2015-12-11 | Dox + HD Mtx (post PAM) | N | null | 330024492 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330010946 | 330011997 | 1.7 | 77 | Palliative (P) | null | 2017-06-21 | CHLORAMBUCIL + RITUXIMAB | null | N | 330024495 | BENDAMUSTINE |
| 330010947 | 330005907 | 1.08 | 0 | Curative (C) | 2015-06-14 | 2015-06-17 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 2 | N | 330024539 | IVADO |
| 330010948 | 330005909 | 1.7 | 60.4 | Palliative (P) | 2014-05-26 | 2014-05-28 | Cisplatin+Doxorubicin+Etoposide 28d | 02 | N | 330024541 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330010949 | 330005914 | 0 | 67 | Curative (C) | 2015-08-26 | 2015-08-30 | R Chlorambucil | N | N | 330024564 | VIDE |
| 330010950 | 330005915 | 1.57 | 65 | Adjuvant (A) | null | 2016-04-18 | Clofarabine + Cytarabine | N | N | 330024564 | UKALL2014 |
| 330010953 | 330005918 | 1.85 | 74.6 | Palliative (P) | 2014-06-03 | 2014-06-07 | Cyclophosphamide oral | 2 | N | 330024605 | CARBOPLATIN + CETUXIMAB + FU |
| 330010954 | 330009224 | null | 55.4 | Disease modification (D) | 2013-08-17 | 2013-11-24 | Clofarabine + Cytarabine | N | null | 330024607 | PAC-E |
| 330010955 | 330011012 | 1.82 | 71 | Curative (C) | 2014-05-29 | 2014-11-23 | CHLORAMBUCIL + RITUXIMAB | 02 | N | 330024608 | BORTEZOMIB + RITUXIMAB |
| 330010956 | 330009227 | 1.78 | 12.3 | Curative (C) | 2015-02-26 | 2015-03-26 | IDARUBICIN | N | N | 330024611 | BEAM |
| 330010957 | 330009227 | null | 87.75 | Radical (R) | 2016-12-11 | 2016-12-11 | Mercaptopurine | N | null | 330024611 | NILOTINIB |
| 330010958 | 330005925 | 1.71 | null | Palliative (P) | null | 2017-11-22 | Aldesleukin | N | N | 330024671 | IDARUBICIN |
| 330010959 | 330005926 | 1.65 | 95.2 | Curative (C) | 2015-05-06 | 2015-05-06 | EMA/CO | 2 | N | 330024676 | FCARBOST |
| 330010960 | 330005930 | 1.71 | 15.9 | Curative (C) | 2014-05-01 | 2014-05-04 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | null | 330024744 | DACTINOMYCIN + CYCLO + VINCRISTINE |
| 330010961 | 330012890 | 1.6 | 108 | Palliative (P) | 2017-01-21 | 2017-01-21 | Cytarabine Low Dose | 02 | N | 330024755 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330010962 | 330005933 | 1.72 | 101 | Curative (C) | 2013-07-03 | 2013-07-19 | Topotecan (intravenous) | N | N | 330024769 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330010963 | 330005936 | 1.6 | 59 | Curative (C) | 2014-05-23 | 2014-05-23 | ALL UKALL2011 Consolidation A | N | N | 330024785 | DOXORUBICIN + HD MTX |